Security key
82686Q101
Silence Therapeutics plc - Ordinary share, nominal value 0.05 GBP per share (SLN)
CUSIP: 82686Q101
Q2 2022 13F Holders as of 30 Jun 2022
- Security type / class
- Equity / Ordinary share, nominal value 0.05 GBP per share
- Total 13F shares
- 10,367,019
- Total 13F value
- $116,349,742
- Share change
- -1,816,175
- SEC-reported price per share
- $11.85
- Number of holders
- 24
- Value change
- -$33,812,496
- Number of buys
- 9
- Number of sells
- 11
- Shares outstanding
- 141,918,771
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2022
Institutions
24
Top holders
10
SLN full security history
Ownership snapshot
Full 13F holder table
Silence Therapeutics plc SEC filings
Silence Therapeutics plc company facts
Broader feeds
Ownership snapshot
Top reported holders of SLN - Silence Therapeutics plc - Ordinary share, nominal value 0.05 GBP per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lombard Odier Asset Manag...
Disclosed value leader
Lombard Odier Asset Manag...
Comparable rows
15/15
Latest evidence
31 Mar 2022
13F
Lead comparable stake: 2.6%
Showing 1-6 of 15 holder rows.
Quick read
Lombard Odier Asset Management (USA) Corp leads the comparable SEC ownership view at 2.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lombard Odier Asset Management (USA) Corp's linked filing trail.
Comparable ownership
Top 5
Lombard Odier Asset Management (U...
2.6%
Lombard Odier Asset Management (E...
1.1%
GOLDMAN SACHS GROUP INC
0.68%
Deep Track Capital, LP
0.67%
Frazier Life Sciences Management,...
0.62%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lombard Odier Asset Management (USA) Corp |
13F
Company
|
2.6%
|
$55,692,000
3,632,234 shares
|
— | 31 Mar 2022 |
| Lombard Odier Asset Management (Europe) Ltd |
13F
Company
|
1.1%
|
$29,669,000
1,561,551 shares
|
— | 31 Mar 2022 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
0.68%
|
$18,350,000
965,815 shares
|
— | 31 Mar 2022 |
| Deep Track Capital, LP |
13F
Company
|
0.67%
|
$18,080,000
951,580 shares
|
— | 31 Mar 2022 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
0.62%
|
$16,742,000
881,173 shares
|
— | 31 Mar 2022 |
| BVF INC/IL |
13F
Company
|
0.47%
|
$12,667,000
666,666 shares
|
— | 31 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
24
Shares
10,367,019
Rows available
24
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
25
Q2 2022 holders
24
Holder diff
-1
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q2 2022 value | Value change | Value Chg % |
|---|